Intracranial metastases account for 7%-17% of intracranial tumors. The primary tumors are most commonly lung cancer and breast cancer, and the others are kidney and adrenal gland, digestive tract, skin, ovary, prostate, thyroid, uterus and bone in that order. There are still 10%-20% of cases in which the primary tumors are difficult to identify, and even autopsy cannot detect them. The incidence of each organ reported in foreign comprehensive literature (8414 cases) was 45.58% for lung cancer, 9.38% for breast cancer and 11.99% for gastrointestinal tract carcinoma. Brain metastasis is the most common complication of lung cancer, and its incidence increases significantly with the increase of lung cancer incidence, and about 20%-50% of lung cancer patients have brain metastasis. Brain metastases are most common in adenocarcinoma, followed by small cell lung cancer (SCLC). Treatment of intracranial metastases: for single brain metastases, the primary tumor can be eradicated and there is no other metastases: surgery + radiotherapy + chemotherapy; for patients with brain metastases resistant to radiotherapy, or if the intracranial metastases are large in size and cause a significant increase in intracranial pressure, or if the metastases are secondary to intracranial hemorrhage and cause rapid deterioration; if there is more than one metastasis, the one that may threaten the patient’s life can be removed; for treatment of the primary metastases: if the condition allows If the tumor or edema blocks the cerebrospinal fluid circulation pathway causing hydrocephalus, shunt surgery is feasible; {cranial pressure meningeal metastases, if survival is not more than 6 weeks without treatment, ventriculoperitoneal shunt + lateral ventricular chemotherapy pump placement, whole brain radiotherapy 46Gy/23f, and Temozolomide 100mg/d concurrent chemotherapy and cytarabine 50mg pump once/week. The average survival was 5 months.